DG Comp punishes Lundbeck over pay-for-delay

The European Commission has fined pharmaceutical company Lundbeck €94 million and several generic drug makers €52 million for delaying the entry of generic drugs to the EU market. It is the first fine issued in a reverse-payment case under European law.

Premium Subscription required to view this article

This content can only be accessed by Premium subscribers.

This content is part of the gcr archive and can only be accessed by subscribers with a Premium Subscription.


If you are a subscriber, please login:


You must Subscribe or Log In to make comments.

Comment Terms & Conditions

Law Business Research Ltd

87 Lancaster Road, London
W11 1QQ, UK
Queen's Award logo American Bar Association strategic partner logo

Copyright © 2015 Law Business Research Ltd. All rights reserved. |

87 Lancaster Road, London, W11 1QQ, UK | Tel: +44 207 908 1188 / Fax: +44 207 229 6910 |